These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 793999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ, Laszt A, Paran E, Ben Ari J, Goren Y, Modan M.
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL, Strocchi E, Ambrosioni E, Magnani B.
    Int J Clin Pharmacol Res; 1983 Aug; 3(1):35-9. PubMed ID: 6384071
    [Abstract] [Full Text] [Related]

  • 4. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS, Farsky K, Bouchard S, Lalonde Y, Brookman S.
    Clin Ther; 1985 Aug; 7(2):199-204. PubMed ID: 3886142
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [A new antihypertensive agent used in a clinical setting].
    Wetzels E, Raschig A, Kaiser HJ.
    Med Klin; 1980 Sep 12; 75(19):688-92. PubMed ID: 7001207
    [Abstract] [Full Text] [Related]

  • 11. [Guanfacine (Estulic) in the monotherapy of essential hypertension, grades I and II, according to WHO].
    Mayer K, Lupínek Z, Janousek S, Podrouzková B.
    Cas Lek Cesk; 1984 Oct 26; 123(43):1306-11. PubMed ID: 6391673
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical trial of a new antihypertensive preparation: guanfacine].
    Rengo F, Ricciardelli B, Spirito G, Volpe M, Morrone G, Trimarco B, Condorelli M.
    Boll Soc Ital Cardiol; 1979 Oct 26; 24(10):1097-102. PubMed ID: 400394
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG, Bloxham CA, Walker JM.
    Pharmatherapeutica; 1981 Oct 26; 2(8):513-6. PubMed ID: 7019931
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus.
    Dvorák I, Podrouzková B, Kocourková J, Kubesová H, Spác J, Nĕmcová H, Blaha M.
    Cor Vasa; 1987 Oct 26; 29(4 Suppl 1):30-6. PubMed ID: 3315448
    [Abstract] [Full Text] [Related]

  • 20. Long-term antihypertensive therapy with guanfacine.
    Szám I, Holló J.
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug 26; 20(8):388-92. PubMed ID: 6749702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.